EDEN PRAIRIE, Minn.,
March 3, 2022 /PRNewswire/ --
NeuroOne Medical Technologies Corporation (NASDAQ: NMTC)
("NeuroOne" or the "Company"), a medical technology company focused
on improving surgical care options and outcomes for patients
suffering from neurological disorders, today announced that it is
scheduled to attend two investor conferences during the month of
March 2022.
Oppenheimer
32nd Annual Virtual Healthcare Conference
|
Date and
time:
|
March 16, 2022, at
1:20 p.m. ET.
|
Location:
|
Virtual
|
Format:
|
Presentation, 1-on-1
meetings
|
34th Annual ROTH
Conference
|
Dates:
|
March 13-15,
2022
|
Location:
|
Ritz-Carlton, Laguna
Niguel, California
|
Format:
|
1-on-1 meetings and
select analyst fireside chats
|
Registration;
|
Contact your ROTH
representative
|
During the conferences, NeuroOne Chief Executive Officer
Dave Rosa will discuss the Company's
high-definition, minimally invasive thin-film Evo® Cortical
Electrodes for the diagnosis of various neurological conditions.
Leveraging its game-changing technology developed in collaboration
with Mayo Clinic, NeuroOne's upcoming commercial and development
catalysts include the Evo® sEEG diagnostic line (if cleared by
the FDA) and further development of a combination diagnostic and
ablation electrode system, as well as the potential for technology
adaptation and entry into artificial intelligence and machine
learning markets.
About NeuroOne® Medical Technologies Corporation
NeuroOne is a medical technology company focused on the
development and commercialization of minimally invasive and
high-definition/high-precision solutions for epilepsy, Parkinson's
disease, dystonia, essential tremors, and chronic pain due to
failed back surgeries. These solutions include electrodes that have
the potential to reduce the number of hospitalizations, surgical
procedures and cost while improving patient outcomes due to their
potential for offering combination diagnostic and therapeutic
functions such as EEG recording and tissue ablation and/or chronic
stimulation. A combination recording and RF ablation technology is
currently under development. In addition, NeuroOne recently
announced initial results of testing of its electrodes for long
term recording and stimulation. The Company is also investigating
the potential application of its technology for artificial
intelligence and machine learning. Visit n1mtc.com.
Forward Looking Statements
This press release may include forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as
amended. Except for statements of historical fact, any information
contained in this presentation may be a forward–looking statement
that reflects the Company's current views about future events and
are subject to known and unknown risks, uncertainties and other
factors that may cause our actual results, levels of activity,
performance or achievements to be materially different from the
information expressed or implied by these forward-looking
statements. In some cases, you can identify forward–looking
statements by the words or phrases "may," "might," "will," "could,"
"would," "should," "expect," "intend," "plan," "objective,"
"anticipate," "believe," "estimate," "predict," "project,"
"potential," "target," "seek," "contemplate," "continue, "focused
on," "committed to" and "ongoing," or the negative of these terms,
or other comparable terminology intended to identify statements
about the future. Forward–looking statements may include statements
regarding clinical and pre-clinical testing, NeuroOne's business
strategy, regulatory clearance, market size and potential growth.
Although the Company believes that we have a reasonable basis for
each forward-looking statement, we caution you that these
statements are based on a combination of facts and factors
currently known by us and our expectations of the future, about
which we cannot be certain. Our actual future results may be
materially different from what we expect due to factors largely
outside our control, including risks that our technology will not
perform as expected based on results of our pre-clinical testing;
uncertainties inherent in the development process of our
technology; risks related to changes in regulatory requirements or
decisions of regulatory authorities; risks that we may not receive
certain regulatory clearances; risks that we may not have
accurately estimated the size and growth potential of the markets
for our technology; and other risks and uncertainties related to
market and other conditions, the impact of general economic,
industry or political conditions in the United States or
internationally and those described under the heading "Risk
Factors" in our filings with the Securities and Exchange
Commission. These forward–looking statements speak only as of the
date of the podcast and the Company undertakes no obligation to
revise or update any forward–looking statements for any reason,
even if new information becomes available in the future.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/neuroone-to-present-its-game-changing-neuroscientific-technology-at-the-oppenheimer-32nd-annual-healthcare-conference-and-34th-annual-roth-conference-301494042.html
SOURCE NeuroOne Medical Technologies Corporation